EP1461057A1 - Formulation topique contre les demangeaisons et procede de preparation de celle-ci - Google Patents
Formulation topique contre les demangeaisons et procede de preparation de celle-ciInfo
- Publication number
- EP1461057A1 EP1461057A1 EP02796955A EP02796955A EP1461057A1 EP 1461057 A1 EP1461057 A1 EP 1461057A1 EP 02796955 A EP02796955 A EP 02796955A EP 02796955 A EP02796955 A EP 02796955A EP 1461057 A1 EP1461057 A1 EP 1461057A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- formulation
- tea tree
- oil
- glycol carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Definitions
- a topical anti-itch formulation and a process for the preparation thereof are provided.
- corticosteroids such as hydrocortisone.
- dexametliasone or betamethasone are generally used.
- the side effects/adverse effects of long term use of corticosteroids such as skin thi ing or atrophy are clinically well known and reported (Medicine in practice. Issue 1, pg 14).
- centella asiatica is well known to have medicinal properties. Centella whole extract isolated from the herb is purified for therapeutic use. Purified centella extract enriched with its triterpen ⁇ actives viz asiaticocide, asiatic acid and madeeassie acid in 1% is reported to be used in healing of various types of wounds o ⁇ ulcers or in disinfection thereof or in cicatrisation thereof by regeneration or in stimulation of skin and also as a. scar minimising agent ("Clinical study of a new antikeloid agent", Annals of Plastic Surgery, Vol 3, No 1, pp 13 to 21, by Bbsse J P et al, French Patent No 2594690A, European Patent No 22046A, Belgium Patent No 699410A). Preparation of purified centella extract by techniques like nanofiltrat m, liquid- liquid extraction or column cliromatography is laborious, time consui iing and expensive thus rendering purified centella extract very expensive.
- Tea tree oil in 0.2% and above is reported to exhibit antibacterial properties and is used in cosmetics and toiletries ('Optimising the activity of tea tree oil in cosmetics and toiletries" - a Paper presented at the 4th Joint Conference of Australian and New Zealand Societies of Cosmetic Chemists, Surfer's Paradise. Australia, 1994).
- An object of the. invention is to provide a topical anti-itch formulation, which provides fast and effective relief from itching.
- Another object of the invention is to provide a topical anti-itch formulation, which also provides cooling and moisturising effects.
- Another object of the invention is to provide a topical anti-itch formulation, which is safe for use over a long period of time.
- Another object of the invention is to provide a topical anti-itch I rmuMon, which is economical.
- Another object of the invention is to provide a topical anti-itch formulation j Whicli is easy and convenient to use.
- Another object of the invention is to provide a process for preparing a topical anti-itch formulation which is safe for use over a long period of time.
- Another object of the invention is to provide a process for preparing a topical anti-itch formulation which is economical.
- Another object of ⁇ ie invention is to provide a process for preparing a topical anti-itch formulation which is easy and convenient to use.
- a topical anti-itch formulation comprising centella asiatica whole extract in 0.1- 2% by weight and tea tree oil in 0.1 - 2% by weight in combination with formulating agents.
- a process for preparing a topical anti-itch formulation comprising mixing centella asiatica whole extract in 0.1-2% by weight and tea tree oil in 0.1-2% by weight with formulating agents ai 25-80°C.
- the formulation may comprise a cooling cum moisturising agent in 0.3 - 2% by weight and the process may comprise mixing a cooling cum moisturising agent in 0.3 - 2% by weight with the centella asiatica whole extract and tea tree oil and foimularing agents.
- the cooling cum moisturising agent may be men hone ⁇ ycerine acetal or a mixture of 5-methyl-2 ⁇ (l-methyIemyl)-cyclohexanol, menthol propylene glycol carbonate, menthol ⁇ thylene glycol carbonate and peppermint oil, herein after referred to as menthol-mint compound.
- menthol-mint compound a mixture of 5-methyl-2 ⁇ (l-methyIemyl)-cyclohexanol, menthol propylene glycol carbonate, menthol ⁇ thylene glycol carbonate and peppermint oil, herein after referred to as menthol-mint compound.
- the menthone glycerine acetal or meitfhol-mint compound is in 0.3-0.5% by weight.
- Formulating agents used to prepare the formulation may be anliydrous lanoline, ethylene glycol monostearate, mineral oil, carbomer, carbopol, propylene glycol, isopropyl myristate, myristyi myristate, sodium dioctyl sulfosuccinate (DOSS), bee wax, borax, absolute alcohol, cetyl alcohol, stearyl alcohol, a mixture of phenoxyethanol, methyl paraben, ethyl paraben, propyl paraben and butyl paraben, ethylene dia iiie tetracetic acid (EDT ), glyceryl monostearate, benzophenone, benzyl alcohol, propenic acid polymer, polysorbate 20, 2-amino-2-methyl-l-propanol, polyethyleneg ycol-40- hydrogenated castor oil, monomer of homopropenic acid, sorbiton monostearate, glycerine or butylated
- Dyes like amaranth or brilliant blue or perfumes such as “BBA 1022” of Bush Boake Allen, USA; “BV 2723” of Takasago, Japan or “Cora ⁇ Hto” of Harmer & Reimer, India also may be added to the formulation which may be a el ⁇ cream or lotion.
- the centella asiatica whole extract is in 1 -2% by weight and tea tree o ⁇ is in 0.2 - 2% by weight.
- the mixing of the ingredients of the formulation is carried out at 25-75°C.
- the formulation of the invention provides fast and effective relief from itching. Because it is based on cenie]ll& asiatica whole extract and tea tree oil, both of which are of plant origin, it is safe for use over a long period of time without adverse/side effects. It is economical due to the use of whole extract of centella asiatica which is easily available and cheap. Due to the cooling cum moisturising agent, the affected areas treated with the formulation of the invention experience cooling and soothing effects which provide a sense of iimnediate relief from itching. Besides these areas also remain moisturised thereby facilitating penetration of the actives into the skin thus acclerating healing. It is also convenien to use or apply as a cream, gel or lotion.
- Centella asiatica whole extract 1.0 (Amsar Pvt Ltd, ⁇ ndore, India) Tea tree oil (Southern Cross
- DOSS was dissolved in hot water (150 gms) at 80°C.
- propylene glycol at 70°C phenonip and polysorbate 20 were added and this solution was mixed with the solution of DOSS.
- Centella asiatica whole extract followed by carbopol were dispersed in the above solution and the dispersion stirred for 45 minutes.
- mineral oil at 70°C tea tree oil and ethylene glycol monostearate, isopropyl myristate, lanoline anhydrous and "Frescolate” were added and stirred to form an emulsion.
- the emulsion was mixed with the above dispersion comprising centella and cooled to 25°C.
- 10% NaOH was added to adjust the pH to 6.68 and the formulation was made upto 100 gms by adding water to obtain a cream.
- Isopropyl myristate 3.5 A iiiixtur ⁇ of phenoxyethanol, methyl paraben, ethyl paraben, propyl paraben and butyl paraben ("Phenonip",
- An aqueous phase was prepared by miring polysorbate 20 glycerine, centella asiatica whole extract phenonip, EDTA and BHT in water at 70 - 75°C.
- An oil phase was prepared by mixing mineral oil, bee wax, glyceryl monostearate, sorbiton monostearate, tea tree oil, myristyi myristate, isopropyl myristate and "Frescolate" at 25°C.
- the oil and aqueous phases were mixed together followed by rnix ng with borax, perfiune, c ⁇ tyl and stearyl alcohol to give a lotion.
- Glycerine 6.0 A mixture of phenoxyethanol, methyl paraben, ethyl paraben, propyl paraben and butyl paraben ("Phenonip",
- Menthol-mint compound (“Opta int” of Harmer & Reimer, Maharashtra, India) 0.3
- the volunteers provided ratings on a scale of 0-4 with respect to the parameters of swelling, redness, pain, itching and erythema wherein "0" implied 100%, “1” implied 25%, “2” implied 50%, “3” implied 75% and "4" implied 0% maaifest- ⁇ tion. of the above sa para eters.
- the &v «stag Tsafcsngjs of the various parameters by the volunteers in the three groups using P, G and H at various time intervals were as shown in the following Table 2 Table
- the anti-itch activity of the formulation of the invention is higher when compared to placebo and comparable with hydrocortisone butyrate.
- a consumer use test was conducted for mosquito bite on 100 volunteers including women and children under 15 years of age. 50 volunteers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Birds (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU9704701 | 2001-12-05 | ||
AU97047/01A AU771707B2 (en) | 2001-12-05 | 2001-12-05 | A topical anti-itch formulation and a process for the preparation thereof |
PCT/IN2002/000228 WO2003047609A1 (fr) | 2001-12-05 | 2002-12-04 | Formulation topique contre les demangeaisons et procede de preparation de celle-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1461057A1 true EP1461057A1 (fr) | 2004-09-29 |
Family
ID=3764370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02796955A Withdrawn EP1461057A1 (fr) | 2001-12-05 | 2002-12-04 | Formulation topique contre les demangeaisons et procede de preparation de celle-ci |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1461057A1 (fr) |
JP (1) | JP2005515204A (fr) |
CN (1) | CN1263474C (fr) |
AU (1) | AU771707B2 (fr) |
WO (1) | WO2003047609A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10306987A1 (de) * | 2003-02-19 | 2004-09-02 | Bonapharm Gmbh | Zubereitung auf Basis von Teebaumöl sowie Verfahren zu ihrer Herstellung und ihre Verwendung |
ITMI20051396A1 (it) * | 2005-07-21 | 2007-01-22 | Svas Biosana Srl | Garza medicata |
GB2439385B (en) * | 2006-06-20 | 2010-09-29 | Sukhdip Singh Sidhu | Menthol in aqueous cream |
JP5565995B2 (ja) * | 2006-09-29 | 2014-08-06 | 小林製薬株式会社 | 鎮痒剤 |
CN100459972C (zh) * | 2006-11-07 | 2009-02-11 | 华南农业大学 | 一种祛痘润肤乳及其制备方法 |
CN113924108B (zh) * | 2019-07-15 | 2023-01-17 | 宝洁公司 | 包含积雪草的局部用护肤组合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR4209M (fr) * | 1965-03-03 | 1966-06-06 | ||
FR2459661A1 (fr) * | 1979-06-25 | 1981-01-16 | Phybiocit Laboratoires | Nouvelle composition medicamenteuse a base de plantes, et procede de preparation |
JPH08133952A (ja) * | 1994-11-07 | 1996-05-28 | Shiseido Co Ltd | 皮膚外用剤 |
DE19654635C1 (de) * | 1996-12-28 | 1998-01-08 | Singh Verma Shyam B | Kosmetische Zubereitungen enthaltend Extrakte von Phyllanthus emblica und Centella asiatica |
DE19910990A1 (de) * | 1999-03-12 | 2000-09-14 | Schwarz Monika | Heilmittel auf Teebaumölbasis |
DE29913476U1 (de) * | 1999-08-02 | 1999-09-23 | Breithaupt, Gunter, 49134 Wallenhorst | Präparat zur Behandlung von Hauterkrankungen |
KR100377319B1 (ko) * | 2000-02-29 | 2003-03-26 | 주식회사 네이쳐프러스 | 알레르기성 비염 치료용 에센셜 오일 조성물 |
-
2001
- 2001-12-05 AU AU97047/01A patent/AU771707B2/en not_active Ceased
-
2002
- 2002-12-04 CN CNB028022971A patent/CN1263474C/zh not_active Expired - Fee Related
- 2002-12-04 EP EP02796955A patent/EP1461057A1/fr not_active Withdrawn
- 2002-12-04 WO PCT/IN2002/000228 patent/WO2003047609A1/fr active Application Filing
- 2002-12-04 JP JP2003548864A patent/JP2005515204A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO03047609A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU9704701A (en) | 2003-06-12 |
CN1263474C (zh) | 2006-07-12 |
CN1516593A (zh) | 2004-07-28 |
AU771707B2 (en) | 2004-04-01 |
JP2005515204A (ja) | 2005-05-26 |
WO2003047609A1 (fr) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5853732A (en) | Pharmaceutical compositions containing kukui nut oil | |
US20060029627A1 (en) | Antipruritic composition and wound-healing-promoting composition | |
US20170246106A1 (en) | Methods and compositions for maintaining and improving the health of skin | |
US20190021961A1 (en) | Water-in-oil emulsion | |
KR101961608B1 (ko) | 말캉니 오일과 시프리올 오일을 유효성분으로 포함하는 통증 완화용 조성물 | |
CN113197836A (zh) | 一种保湿舒缓止痒护肤乳霜及其制备方法 | |
CN113440433A (zh) | 冰沙状卸妆组合物及其制备方法 | |
CN114146014A (zh) | 一种复方烟酸薄荷酯植物多糖乳膏及其制备方法 | |
EP1461057A1 (fr) | Formulation topique contre les demangeaisons et procede de preparation de celle-ci | |
US20160101139A1 (en) | Topical treatment for use as a sleep aid | |
US20200030398A1 (en) | Skin care composition | |
US20010014315A1 (en) | Bar soap composition | |
US20050152993A1 (en) | Composition for and method of treatment for skin ailments | |
KR101248520B1 (ko) | 수정분말이 포함된 크림 화장품 조성물 | |
WO2009115216A1 (fr) | Utilisation d'un constituant ou d'un extrait de baobab en cas de maladies de peau | |
US20010005509A1 (en) | Foot cream composition | |
US11191795B2 (en) | Herbal compositions and methods for treating herpes | |
JPH1072312A (ja) | 皮膚外用剤 | |
ES2904222T3 (es) | Composiciones para la piel que comprenden turmeronas | |
CN113995701A (zh) | 一种祛痘和消除痘印的组合物及其制备方法和应用 | |
AU2006200131A1 (en) | Topical composition | |
DE202005014920U1 (de) | Zubereitung, insbesondere pharmazeutische, dermatologische oder kosmetische Zubereitung | |
CA2198667C (fr) | Composition contenant du 3-1-menthoxy propane 1, 2-diol, donnant une sensation rafraichissante | |
JPH08231352A (ja) | 養毛料 | |
RU2111740C1 (ru) | Лечебно-косметическое очищающее средство "мюстела" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040705 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KHAIAT, ALAIN,51, SCIENCE PARK ROAD Inventor name: MANKE, AJIT, SITARAM Inventor name: GADGIL, SANDEEP,JOHNSON & JOHNSON LIMITED Inventor name: THOMAS, MINI,JOHNSON & JOHNSON LIMITED |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KHAIAT, ALAIN,51, SCIENCE PARK ROAD Inventor name: MANKE, AJIT, SITARAM Inventor name: GADGIL, SANDEEP,JOHNSON & JOHNSON LIMITED Inventor name: THOMAS, MINI,JOHNSON & JOHNSON LIMITED |
|
17Q | First examination report despatched |
Effective date: 20081106 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090519 |